Dr. Suhail Nurbhai is chief medical officer at Mission Therapeutics and has worked in all phases of clinical research and development for the past 30 years. He has held roles of increasing responsibility in large pharma (Pfizer, Takeda) and at start-up biotech organizations in both UK and USA, and he has moved translational and clinical projects in multiple therapeutic areas through IND and NDA / MAA approvals. During his time at Pfizer, he was executive director and head of neuroscience clinical R&D at the Groton/New London site in Connecticut. Upon returning to the UK, he was head of clinical and analytical science at Takeda in London with responsibility for all therapeutic areas including neuroscience. During both of these appointments, he was closely involved at the level of projects and governance in multiple clinical programs across several neuroscience indications including Parkinson’s disease, Alzheimer’s disease, addiction, migraine and psychiatric conditions.